Evidence map›Paper›PMID 27761889›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2017

MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report.

Antonella Caivano, Francesco La Rocca, Vittorio Simeon, Marco Girasole, Simone Dinarelli, Ilaria Laurenzana, Angelo De Stradis, Luciana De Luca, Stefania Trino, Antonio Traficante and 7 more

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Irradiation alters extracellular vesicle microRNA load in the serum of patients with leukaemia.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Antonella CaivanoLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy. caivanoa@libero.it.ORCID http://orcid.org/0000-0003-2502-4060
Francesco La RoccaLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy.
Vittorio SimeonLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy.
Marco GirasoleInstitute for the Study of the Structure of Matter, National Research Council (CNR), Rome, Italy.
Simone DinarelliInstitute for the Study of the Structure of Matter, National Research Council (CNR), Rome, Italy.
Ilaria LaurenzanaLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy.
Angelo De StradisInstitute for Sustainable Plant Protection, CNR, Bari, Italy.
Luciana De LucaLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy.
Stefania TrinoLaboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), 85028, Rionero in Vulture, Potenza, Italy.
Antonio TraficanteUnit of Clinical Pathology, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Giovanni D'ArenaDepartment of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Giovanna MansuetoDepartment of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Oreste VillaniDepartment of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Giuseppe PietrantuonoDepartment of Onco-Hematology, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Luca LaurentiDepartment of Hematology, Catholic University of the Sacred Heart, Rome, Italy.
Luigi Del VecchioCEINGE-Biotecnologie Avanzate scarl and Department of Molecular Medicine and Medical Biotechnologies, Federico II University, Naples, Italy.
Pellegrino MustoScientific Direction, IRCCS-CROB, Rionero in Vulture, Potenza, Italy.
Centro di Riferimento Oncologico della Basilicata · ITNational Research Council · ITCeinge Biotecnologie Avanzate (Italy) · ITInstitute for Sustainable Plant Protection · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of extracellular vesicles (EVs) from body fluids as "liquid biopsies" is emerging as a promising approach for the diagnosis, prognosis and therapeutic monitoring of cancer patients. MicroRNA-155 (miR155), a non-coding transcript of the B-cell integration cluster (BIC) gene, has been reported to play a critical role in the pathogenesis of several types of hematologic malignancies (HMs) in which high miR155 levels have been found. At yet, however, the EV miR155 level and its putative clinical relevance in sera of HM patients have not been reported.

methodsEVs from sera of representative patients with eight different HMs and healthy subjects (controls) were isolated using differential centrifugation. The identity and quality of the EVs were verified by atomic force and transmission electron microscopy. The EV miR155 levels were measured by quantitative RT-PCR. The sensitivity, specificity and area under the curve (AUC) of differences in EV miR155 levels were determined using ROC curve analyses.

resultsWe found that the EV miR155 levels were significantly higher in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and Waldenström's macroglobulinemia (WM) cases compared to controls. Conversely, we found that the EV miR155 levels were significantly lower in myelodysplastic syndrome (MDS) and multiple myeloma (MM) cases. No differences were found in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or Hodgkin's Lymphoma (HL) cases compared to controls. EV miR155 ROC curve analyses revealed significantly different patterns in CLL and AML cases compared to controls, and in AML cases compared to MDS cases (p = 0.004, p = 0.01 and p = 0.04, respectively). In addition, we found that high EV miR155 levels correlated with high white blood cell counts in AML patients.

conclusionOur data indicate that EV miR155 may serve as an attractive new, non-invasive diagnostic biomarker in human hematologic malignancies.

Indexed as

AdolescentAdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorExtracellular VesiclesFemaleHematologic NeoplasmsHumansMaleMicroRNAsMicroscopy, Atomic ForceMicroscopy, Electron, TransmissionMiddle AgedReal-Time Polymerase Chain ReactionBiomarkers, TumorMicroRNAsMIRN155 microRNA, humanAcute myeloid leukemiaChronic lymphocytic leukemiaExtracellular vesiclesmiR155Myelodysplastic syndromeWaldenström’s macroglobulinemia

Identifiers

PMID27761889
PMCPMC13001561
OpenAlexW2533551028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.